Dengue vaccine development

• Verfasst von: Wilder-Smith, Annelies [VerfasserIn]
• Titel: Dengue vaccine development
• Titelzusatz: challenges and prospects
• Verf.angabe: Annelies Wilder-Smith
• Jahr: 2022
• Umfang: 7 S.
• Fussnoten: Gesehen am 11.10.2022
• Titel Quelle: Enthalten in: Current opinion in infectious diseases
• Ort Quelle: London : Lippincott Williams & Wilkins, 1988
• Jahr Quelle: 2022
• Band/Heft Quelle: 35(2022), 5, Seite 390-396
• ISSN Quelle: 1473-6527
• ISSN Quelle: 1535-3877
• DOI: doi:10.1097/QCO.0000000000000871
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1818573334

Abstract

Purpose of review - Dengue vaccine development is a high public health priority. To date, no dengue vaccine is in widespread use. Here we review the challenges in dengue development and the latest results for the second-generation dengue vaccines. - Recent findings - The biggest hurdle is the immunological interaction between the four antigenically distinct dengue serotypes. The advantages of second-generation dengue vaccines are the inclusion of nonstructural proteins of the dengue backbone and a more convenient dosing with reduced numbers of doses needed. - Summary - Although dengue-primed individuals can already benefit from vaccination with the first licensed dengue vaccine CYD-TDV, the public health need for the dengue-naive population has not yet been met. The urgent need remains to identify correlates of both protection and enhancement; until such correlates have been identified, all second-generation dengue vaccines still need to go through full phase 3 trials. The 5-year efficacy and safety data for both second-generation dengue vaccines are imminent.